Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | — | 1 | 5 | — | — | 6 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 5 | — | — | 6 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 5 | — | — | 6 |
Anhedonia | D059445 | — | R45.84 | — | — | 4 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Smoking | D012907 | EFO_0004318 | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Drug common name | Aticaprant |
INN | aticaprant |
Description | Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder. A regulatory application for approval of the medication is expected to be submitted by 2025. Aticaprant is taken by mouth.
|
Classification | Small molecule |
Drug class | kappa opiod receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1 |
PDB | — |
CAS-ID | 1174130-61-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1921847 |
ChEBI ID | — |
PubChem CID | 44129648 |
DrugBank | DB12341 |
UNII ID | DE4G8X55F5 (ChemIDplus, GSRS) |